Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C E Ford

Showing results (81-90 of 90) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 90 results.
Journal of Medicinal Chemistry|May 5, 2000
Substituted benzamide inhibitors of human rhinovirus 3C protease: structure-based design, synthesis, and biological evaluationS H Reich, T Johnson, M B Wallace, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|October 20, 2011
Improving the diagnosis of pulmonary tuberculosis in HIV-infected individuals in Ho Chi Minh City, Viet NamD T M Nguyen, N Q Hung, L T Giang, et al.
Journal of Medicinal Chemistry|July 21, 1998
Tripeptide aldehyde inhibitors of human rhinovirus 3C protease: design, synthesis, biological evaluation, and cocrystal structure solution of P1 glutamine isosteric replacementsS E Webber, K Okano, T L Little, et al.
American Journal of Hypertension|April 1, 1996
Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research GroupB R Davis, J A Cutler, D J Gordon, et al.
Bioorganic & Medicinal Chemistry Letters|October 10, 2001
Design and synthesis of irreversible depsipeptidyl human rhinovirus 3C protease inhibitorsS E Webber, J T Marakovits, P S Dragovich, et al.
Bioorganic & Medicinal Chemistry Letters|January 15, 2000
Structure-based design of ketone-containing, tripeptidyl human rhinovirus 3C protease inhibitorsP S Dragovich, R Zhou, S E Webber, et al.
Journal of Medicinal Chemistry|April 10, 1999
Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacementsP S Dragovich, T J Prins, R Zhou, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 29, 1999
Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypesD A Matthews, P S Dragovich, S E Webber, et al.
Journal of Medicinal Chemistry|July 21, 1998
Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 2. Peptide structure-activity studiesP S Dragovich, S E Webber, R E Babine, et al.
Journal of Medicinal Chemistry|July 21, 1998
Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 1. Michael acceptor structure-activity studiesP S Dragovich, S E Webber, R E Babine, et al.
Pageof 9

Showing results (81-90 of 90) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 90 results.
Journal of Medicinal Chemistry|May 5, 2000
Substituted benzamide inhibitors of human rhinovirus 3C protease: structure-based design, synthesis, and biological evaluationS H Reich, T Johnson, M B Wallace, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|October 20, 2011
Improving the diagnosis of pulmonary tuberculosis in HIV-infected individuals in Ho Chi Minh City, Viet NamD T M Nguyen, N Q Hung, L T Giang, et al.
Journal of Medicinal Chemistry|July 21, 1998
Tripeptide aldehyde inhibitors of human rhinovirus 3C protease: design, synthesis, biological evaluation, and cocrystal structure solution of P1 glutamine isosteric replacementsS E Webber, K Okano, T L Little, et al.
American Journal of Hypertension|April 1, 1996
Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research GroupB R Davis, J A Cutler, D J Gordon, et al.
Bioorganic & Medicinal Chemistry Letters|October 10, 2001
Design and synthesis of irreversible depsipeptidyl human rhinovirus 3C protease inhibitorsS E Webber, J T Marakovits, P S Dragovich, et al.
Bioorganic & Medicinal Chemistry Letters|January 15, 2000
Structure-based design of ketone-containing, tripeptidyl human rhinovirus 3C protease inhibitorsP S Dragovich, R Zhou, S E Webber, et al.
Journal of Medicinal Chemistry|April 10, 1999
Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacementsP S Dragovich, T J Prins, R Zhou, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 29, 1999
Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypesD A Matthews, P S Dragovich, S E Webber, et al.
Journal of Medicinal Chemistry|July 21, 1998
Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 2. Peptide structure-activity studiesP S Dragovich, S E Webber, R E Babine, et al.
Journal of Medicinal Chemistry|July 21, 1998
Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 1. Michael acceptor structure-activity studiesP S Dragovich, S E Webber, R E Babine, et al.
Pageof 9